Literature DB >> 3575605

Psychopathology in prenatally DES-exposed females: current and lifetime adjustment.

A A Ehrhardt, J F Feldman, L R Rosen, H F Meyer-Bahlburg, R Gruen, N P Veridiano, J Endicott, P Cohen.   

Abstract

This report concerns the long-term effects of prenatal exposure to diethylstilbestrol (DES) on overall psychologic functioning in females. Thirty DES-exposed women aged 17-30 years and 30 control women with a history of abnormal Pap smear findings were interviewed with the SADS-L and completed the SCL-90-R and the PRI-Q. Both DES and PAP women showed elevated symptoms on the SCL-90-R in comparison to published norms and were similar to women with cancer, but their rates of psychiatric disorders (SADS-L/RDC) at the time of the evaluation did not differ from community norms. However, both groups met criteria for Major Depressive Disorder (lifetime) significantly above expectancy, and the DES women reported slightly more episodes than the control group. The DES women also had significantly more problems than the PAP control group in social relations with spouses and other significant persons.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3575605     DOI: 10.1097/00006842-198703000-00008

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  3 in total

1.  Diethylstilbestrol exposure in utero and depression in women.

Authors:  Eilis J O'Reilly; Fariba Mirzaei; Michele R Forman; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2010-03-23       Impact factor: 4.897

2.  Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study.

Authors:  Helene Verdoux; Jacques Ropers; Dominique Costagliola; Françoise Clavel-Chapelon; Xavier Paoletti
Journal:  Psychol Med       Date:  2007-04-04       Impact factor: 7.723

Review 3.  Gender-related behavior in women exposed prenatally to diethylstilbestrol.

Authors:  R R Newbold
Journal:  Environ Health Perspect       Date:  1993-08       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.